JMS Co

JMS Co Equity Growth

The Year-over-Year Equity Growth of JMS Co (7702.T) as of Nov 2, 2026 is 2.19 %. In the previous year, Year-over-Year Equity Growth was 0.65 % — a change of 238.11% (higher).

Equity Growth

2.19 %

YoY

238.11%

Last updated:

Year-over-Year Equity Growth of JMS Co is 2026 2.19 % . Year-over-Year Equity Growth of JMS Co was 2025 0.65 % . It decreases by 238.11% higher compared to the previous year.

The JMS Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2019
1.09 JPY
Jan 1, 2020
1.80 JPY
Jan 1, 2021
7.75 JPY
Jan 1, 2022
6.08 JPY
Jan 1, 2023
4.25 JPY
Jan 1, 2024
5.30 JPY
Jan 1, 2025
0.65 JPY
Jan 1, 2026
2.19 JPY
The JMS Co Equity Growth history
YEAREquity GrowthYoY
2.19 %+238.11%
0.65 %-87.77%
5.30 %+24.68%
4.25 %-30.08%
6.08 %-21.53%
7.75 %+330.19%
1.80 %+64.96%
1.09 %-31.23%
1.59 %+246.64%
0.46 %-122.91%
-2.00 %-168.48%
2.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

Year-over-Year Equity Growth of JMS Co is 2.19 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth JMS Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's JMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — JMS Co

All Key Metrics — JMS Co